Targeting post-transcriptional control for drug discovery

RNA Biology

Volumn 6, Issue 3, 2009, Pages 329-334

  Peltz, Stuart W ^a   Welch, Ellen M ^a   Trotta, Christopher R ^a   Davis, Thomas ^a   Jacobson, Allan ^b  

^a PTC THERAPEUTICS   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

3 UTR; 5 UTR; Cancer; Genetic disorders; mRNA decay; Nonsense suppression; Protein synthesis; RNA

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GENTAMICIN;

CYSTIC FIBROSIS; DUCHENNE MUSCULAR DYSTROPHY; GENE CONTROL; GENE EXPRESSION; HUMAN; NONHUMAN; NONSENSE MUTATION; POST TRANSCRIPTIONAL CONTROL; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; REVIEW; UNTRANSLATED REGION;

EID: 67650506824     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.6.3.8953     Document Type: Review

References (67)

1. DeJong ES, Luy B, Marino JP. RNA and RNA-protein complexes as targets for therapeutic intervention. Curr Top Med Chem 2002; 2:289-302.
2. Vidal L, Blagden S, Attard G, de Bono J. Making sense of antisense. Eur J Cancer 2005; 41:2812-2818
3. Scanlon KJ. Anti-genes: siRNA, ribozymes and antisense. Curr Pharm Biotechnol 2004; 5:415-420
4. Fedorov Y, et al. Off-target effects by siRNA can induce toxic phenotype. RNA 2006; 12:1188-1196 (Pubitemid 43990544)
5. Ulrich H, et al. DNA and RNA aptamers: from tools for basic research towards therapeutic applications. Comb Chem High Throughput Screen 2006; 9:619-632 (Pubitemid 44320411)
6. Yoshizawa S, Fourmy D, Puglisi JD. Structural origins of gentamicin antibiotic action. EMBO J 1998; 17:6437-6448 (Pubitemid 28521780)
7. Aoki H, et al. Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes. Antimicrob. Agents Chemother 2002; 46:1080-1085
8. Hargrove JL, Schmidt FH. The role of mRNA and protein stability in gene expression. FASEB J 1989; 3:2360-2370 (Pubitemid 19263711)
9. Amrani N, Ghosh S, Mangus DA, Jacobson A. Translation factors promote the formation of two states of the closed-loop mRNP. Nature 2008; 453:1276-1280 (Pubitemid 351913593)
10. Jacobson A. In Translational Control, (Hershey JW, Mathews MB, Sonenberg N, eds.,) Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY 1996; 451-480
11. Sachs A. In Translational Control of Gene Expression (Sonenberg N, Hershey JW, Mathews MB, eds.,) Cold Spring Harbor Laboratory Press, Cold Spring Harbor 2000; 447-465
12. Bhattacharyya A, Trotta CR, Peltz SW. Mining the GEMS - a novel platform technology targeting post-transcriptional control mechanisms. Drug Discov Today 2007; 12:553-560 (Pubitemid 47031659)
13. Mehta A, Trotta CR, Peltz SW. Derepression of the Her-2 uORF is mediated by a novel post-transcriptional control mechanism in cancer cells. Genes Dev 2006; 20:939-953
14. Tonra JR, Hicklin DJ. Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy. Immunol Invest 2007; 36:3-23. (Pubitemid 46024914)
15. Loizos N, et al. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther 2005; 4:369-379 (Pubitemid 40443922)
16. Akiri G, et al. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 1998; 17:227-236 (Pubitemid 28371896)
17. Stein I, et al. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol Cell Biol 1998; 18:3112-3119 (Pubitemid 28240484)
18. Levy NS, Chung S, Furneaux H, Levy AP. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 1998; 273:6417-6423 (Pubitemid 28144735)
19. Goldberg-Cohen I, Furneauxb H, Levy AP. A 40-bp RNA element that mediates stabilization of vascular endothelial growth factor mRNA by HuR. J Biol Chem 2002; 277:13635-13640 (Pubitemid 34967963)
20. -/- mouse carrying a human CFTR-G542X transgene. J Mol Med 2002; 80:595-604.
21. Politano L, et al. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol 2003; 22:15-21.
22. Dent KM, et al. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genet A 2005; 134:295-298 (Pubitemid 40470622)
23. Kerem B, Chiba-Falek O, Kerem E. Cystic fibrosis in Jews: frequency and mutation distribution. Genet Test 1997; 1:35-39 (Pubitemid 127526935)
24. Mendell JT, Dietz HC. When the message goes awry: disease-producing mutations that influence mRNA content and performance. Cell 2001; 107:411-414 (Pubitemid 33152776)
25. Wilusz CJ, Wormington M, Peltz SW. The cap-to-tail guide to mRNA turnover. Nature Rev Mol Cell Biol 2001; 2:237-246
26. Jacobson A, Izaurralde E. in Translational Control in Biology and Medicine (Mathews MB, Sonenberg N, Hershey JWB, eds.,) Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY 2007; 659-691
27. Isken O, Maquat LE. Quality control of eukaryotic mRNA: safeguarding cells from abnormal mRNA function. Genes Dev 2007; 21:1833-1856 (Pubitemid 47204924)
28. Weng Y, Czaplinski K, Peltz SW. Genetic and biochemical characterization of mutations in the ATPase and helicase regions of the Upf1 protein. Mol Cell Biol 1996; 16:5477-5490 (Pubitemid 26315068)
29. Weng Y, Czaplinski K, Peltz SW. Identification and characterization of mutations in the UPF1 gene that affect nonsense suppression and the formation of the Upf protein complex but not mRNA turnover. Mol Cell Biol 1996; 16:5491-5506 (Pubitemid 26315069)
30. Wang W, Czaplinski K, Rao Y, Peltz SW. The role of Upf proteins in modulating the translation read-through of nonsense-containing transcripts. EMBO J 2001; 20:880-890 (Pubitemid 32167652)
31. Maderazo AB, He F, Mangus DA, Jacobson A. Upf1p control of nonsense mRNA translation is regulated by Nmd2p and Upf3p. Mol Cell Biol 2000; 20:4591-4603 (Pubitemid 30396107)
32. Kerem E. Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Curr Opin Pulm Med 2004; 10:547-552
33. Ramalho AS, et al. Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am J Respir Cell Mol Biol 2002; 27:619-627 (Pubitemid 35301816)
34. Gorini L, Kataja E. Phenotypic repair by streptomycin of defective genotypes in E. coli. Proc Natl Acad Sci USA 1964; 51:487-493
35. Davies J, Gorini L, Davis BD. Misreading of RNA codewords induced by aminoglycoside antibiotics. Mol Pharmacol 1965; 1:93-106.
36. Manuvakhova M, Keeling K, Bedwell DM. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 2000; 6:1044-1055 (Pubitemid 30471140)
37. Lai CH, et al. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci USA 2004; 101:15676-15681 (Pubitemid 39473547)
38. Hein LK, et al. alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. J Mol Biol 2004; 338:453-462 (Pubitemid 38479642)
39. Keeling KM, et al. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet 2001; 10:291-299 (Pubitemid 32123987)
40. Keeling KM, Bedwell DM. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and p53 cDNAs in a mammalian translation system. J Mol Med 2002; 80:367-376 (Pubitemid 34775375)
41. Sleat DE, Sohar I, Gin RM, Lobel P. Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. Eur J Paediatr Neurol 2001; 5:57-62. (Pubitemid 32677113)
42. Sangkuhl K, et al. Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo. Hum Mol Genet 2004; 13:893-903. (Pubitemid 38628426)
43. Grayson C, et al. In vitro analysis of aminoglycoside therapy for the Arg120stop nonsense mutation in RP2 patients. J Med Genet 2002; 39:62-67
44. Helip-Wooley A, Park MA, Lemons RM, Thoene JG. Expression of CTNS alleles: subcellular localization and aminoglycoside correction in vitro. Mol Genet Metab 2002; 75:128-133 (Pubitemid 34971605)
45. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996; 2:467-469 (Pubitemid 26191920)
46. Howard MT, et al. Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Ann Neurol 2004; 55:422-426 (Pubitemid 38269595)
47. Bedwell DM, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997; 3:1280-1284 (Pubitemid 27508832)
48. Bidou L, et al. Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment. Gene Ther 2004; 11:619-627 (Pubitemid 38455980)
49. Loufrani L, et al. Absence of dystrophin in mice reduces NO-dependent vascular function and vascular density: total recovery after a treatment with the aminoglycoside gentamicin. Arterioscler Thromb Vasc Biol 2004; 24:671-676 (Pubitemid 38451602)
50. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999; 104:375-381 (Pubitemid 29534321)
51. Clancy JP, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001; 163:1683-1692 (Pubitemid 32578776)
52. Wilschanski M, et al. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 2000; 161:860-865 (Pubitemid 30171743)
53. Wilschanski M, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Eng J Med 2003; 349:1433-1441 (Pubitemid 37211058)
54. Wagner KR, et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001; 49:706-711 (Pubitemid 32530236)
55. James PD, et al. Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood 2005; 106:3043-3048 (Pubitemid 41565897)
56. Welch EM, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447:87-91. (Pubitemid 46685839)
57. Sicinski P, et al. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989; 244:1578-1580 (Pubitemid 19189735)
58. Bonetti B, Fu L, Moon J, Bedwell DM. The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae. J Mol Biol 1995; 251:334-345
59. Fearon K, McClendon V, Bonetti B, Bedwell DM. Premature translation termination mutations are efficiently suppressed in a highly conserved region of yeast Ste6p, a member of the ATP-binding cassette (ABC) transporter family. J Biol Chem 1994; 269:17802-17808 (Pubitemid 24206165)
60. McCaughan KK, Brown CM, Dalphin ME, Berry MJ, Tate WP. Translational termination efficiency in mammals is influenced by the base following the stop codon. Proc Natl Acad Sci USA 1995; 92:5431-5435
61. Tate WP, Mannering SA. Three, four or more: the translational stop signal at length. Mol Microbiol 1996; 21:213-219 (Pubitemid 26291528)
62. Losson R, Lacroute F. Interference of nonsense mutations with eukaryotic messenger RNA stability. Proc Natl Acad Sci USA 1979; 76:5134-5137 (Pubitemid 10231832)
63. Kerem E, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372:719-727
64. Amrani N, et al. A faux 3′-UTR promotes aberrant termination and triggers nonsense-mediated mRNA decay. Nature 2004; 432:112-118 (Pubitemid 39490837)
65. Pruitt KD, Maglott DR. RefSeq and LocusLink: NCBI gene-centered resources. Nucleic Acids Res 2001; 29:137-140 (Pubitemid 32054428)
66. Hirawat S, et al. Safety, tolerability and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007; 47:430-444 (Pubitemid 46465953)
67. Du M, et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA 2008; 105:2064-2069